New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:40 EDTALNYAlnylam price target raised to $125 from $82 at Leerink
Leerink raised its price target for Alnylam shares to $125 citing the company's "impressive" partnership with Genzyme. The firm keeps an Outperform rating on the stock.
News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:49 EDTALNYAlnylam resumed with an Outperform at Leerink
Subscribe for More Information
September 16, 2014
08:02 EDTALNYAlnylam presents ALN-CC5 pre-clinical data
Subscribe for More Information
September 15, 2014
08:01 EDTALNYAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
07:21 EDTALNYHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
08:02 EDTALNYAlnylam broadens pipeline with ALN-AGT
Alnylam Pharmaceuticals announced that it is broadening its pipeline with ALN-AGT. In a poster presented at the American Heart Associationís High Blood Pressure Research 2014 Scientific Sessions, Alnylam and collaborators at the Charite Universitatsmedizin in Berlin presented results of an ALN-AGT lead molecule in an established preeclamptic rodent model. The study showed that administration of ALN-AGT resulted in knockdown of maternal AGT in the liver without detectable evidence of fetal drug exposure, significantly improved pregnancy-related hypertension, ameliorated preeclamptic sequelae in the mother such as proteinuria, and improved fetal outcomes.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use